Physician profile
Taylor Powers
NPI 1467166066
$728.68
in general payments reported to CMS, 2019-2025
10 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.64 · 2023: $162 · 2024: $237 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $390.15 | 2024-2025 | Dysport |
| Abbvie INC. | $85.40 | 2023-2024 | |
| Novo Nordisk INC | $46.00 | 2023-2024 | Wegovy, Rybelsus |
| Axsome Therapeutics, INC. | $42.34 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $41.41 | 2023-2024 | Shingrix, Arexvy |
| Urgo Medical North America, LLC | $38.96 | 2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Lilly USA, LLC | $31.63 | 2024 | Jardiance, Zepbound |
| Idorsia Pharmaceuticals US INC | $20.64 | 2022 | |
| Currax Pharmaceuticals LLC | $16.45 | 2023 | Nexletol, Onzetra Xsail, Contrave |
| Pfizer INC. | $15.70 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.